These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 27030211)
1. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-β signalling pathways. Ma B; Cheng H; Gao R; Mu C; Chen L; Wu S; Chen Q; Zhu Y Nat Commun; 2016 Mar; 7():11123. PubMed ID: 27030211 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. Ma B; Chen Y; Chen L; Cheng H; Mu C; Li J; Gao R; Zhou C; Cao L; Liu J; Zhu Y; Chen Q; Wu S Nat Cell Biol; 2015 Jan; 17(1):95-103. PubMed ID: 25438054 [TBL] [Abstract][Full Text] [Related]
3. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway. Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995 [TBL] [Abstract][Full Text] [Related]
4. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2. Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470 [TBL] [Abstract][Full Text] [Related]
5. miR-302/367/LATS2/YAP pathway is essential for prostate tumor-propagating cells and promotes the development of castration resistance. Guo Y; Cui J; Ji Z; Cheng C; Zhang K; Zhang C; Chu M; Zhao Q; Yu Z; Zhang Y; Fang YX; Gao WQ; Zhu HH Oncogene; 2017 Nov; 36(45):6336-6347. PubMed ID: 28745315 [TBL] [Abstract][Full Text] [Related]
6. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer. Yang P; Li Y; Hou J; Wu D; Zeng X; Zeng Z; Zhang J; Xiong Y; Chen L; Yang D; Wan X; Wu Z; Jia L; Liu Q; Lu Q; Zou X; Fang W; Zeng X; Zhou D J Biol Chem; 2024 Jun; 300(6):107309. PubMed ID: 38657867 [TBL] [Abstract][Full Text] [Related]
7. TGF-β Targets the Hippo Pathway Scaffold RASSF1A to Facilitate YAP/SMAD2 Nuclear Translocation. Pefani DE; Pankova D; Abraham AG; Grawenda AM; Vlahov N; Scrace S; O' Neill E Mol Cell; 2016 Jul; 63(1):156-66. PubMed ID: 27292796 [TBL] [Abstract][Full Text] [Related]
8. CMTM5 influences Hippo/YAP axis to promote ferroptosis in glioma through regulating WWP2-mediated LATS2 ubiquitination. Fan Y; Zou HQ Kaohsiung J Med Sci; 2024 Oct; 40(10):890-902. PubMed ID: 39166861 [TBL] [Abstract][Full Text] [Related]
9. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling. Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830 [TBL] [Abstract][Full Text] [Related]
10. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner. Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386 [TBL] [Abstract][Full Text] [Related]
11. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway. Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198 [TBL] [Abstract][Full Text] [Related]
12. Lats2 modulates adipocyte proliferation and differentiation via hippo signaling. An Y; Kang Q; Zhao Y; Hu X; Li N PLoS One; 2013; 8(8):e72042. PubMed ID: 23977200 [TBL] [Abstract][Full Text] [Related]
13. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. Xiao L; Chen Y; Ji M; Dong J J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212 [TBL] [Abstract][Full Text] [Related]
14. Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Li W; Wang L; Katoh H; Liu R; Zheng P; Liu Y Cancer Res; 2011 Mar; 71(6):2162-71. PubMed ID: 21278236 [TBL] [Abstract][Full Text] [Related]
15. BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling. Verma S; Yeddula N; Soda Y; Zhu Q; Pao G; Moresco J; Diedrich JK; Hong A; Plouffe S; Moroishi T; Guan KL; Verma IM Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7363-7370. PubMed ID: 30918126 [TBL] [Abstract][Full Text] [Related]
16. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750 [TBL] [Abstract][Full Text] [Related]
17. LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP. Shi Y; Geng D; Zhang Y; Zhao M; Wang Y; Jiang Y; Yu R; Zhou X J Mol Neurosci; 2019 May; 68(1):38-48. PubMed ID: 30771084 [TBL] [Abstract][Full Text] [Related]
18. Kim E; Kang JG; Kang MJ; Park JH; Kim YJ; Kweon TH; Lee HW; Jho EH; Lee YH; Kim SI; Yi EC; Park HW; Yang WH; Cho JW Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14259-14269. PubMed ID: 32513743 [TBL] [Abstract][Full Text] [Related]
19. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154 [TBL] [Abstract][Full Text] [Related]
20. Growth control: re-examining Zyxin's role in the hippo pathway. Harvey KF Curr Biol; 2015 Mar; 25(6):R230-R231. PubMed ID: 25784041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]